Aromatase inhibitor-induced modulation of breast density: Clinical and genetic effects

British Journal of Cancer

Volumn 109, Issue 9, 2013, Pages 2331-2339

  Henry, N L ^a   Chan, H P ^b   Dantzer, J ^c   Goswami, C P ^c   Li, L ^c   Skaar, T C ^c   Rae, J M ^a   Desta, Z ^c   Khouri, N ^d   Pinsky, R ^b   Oesterreich, S ^e   Zhou, C ^b   Hadjiiski, L ^b   Philips, S ^c   Robarge, J ^c   Nguyen, A T ^c   Storniolo, A M ^c   Flockhart, D A ^c   Hayes, D F ^a   Helvie, M A ^b   Stearns, V ^f   more..

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

aromatase inhibitor; breast cancer; breast density; mammogram; polymorphism

Indexed keywords

AROMATASE; AROMATASE INHIBITOR; DNA; EXEMESTANE; LETROZOLE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; DENSITY; FEMALE; GENETIC VARIABILITY; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHIC PERCENT DENSITY; MAMMOGRAPHY; MULTICENTER STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION;

EID: 84887022249     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.587     Document Type: Article

References (48)

1. Aiello EJ, Tworoger SS, Yasui Y, Stanczyk FZ, Potter J, Ulrich CM, Irwin M, McTiernan A (2005) Associations among circulating sex hormones, insulin-like growth factor, lipids, and mammographic density in postmenopausal women. Cancer Epidemiol Biomarkers Prev 14: 1411-1417.
2. American College of Radiology (2003) American College of Radiology Breast Imaging Reporting and Data System (BI-RADS). 4th edn. American College of Radiology:
3. Reston, VA. Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB, Lockwood GA, Tritchler DL, Yaffe MJ (1995) Quantitative classification of mammographic densities and breast cancer risk: Results from the Canadian National Breast Screening Study. J Natl Cancer Inst 87: 670-675.
4. Boyd NF, Dite GS, Stone J, Gunasekara A, English DR, McCredieMR, Giles GG, Tritchler D, Chiarelli A, Yaffe MJ, Hopper JL (2002) Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med 347: 886-894.
5. Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ (1998) Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 7: 1133-1144.
6. Boyd NF, Martin LJ, Li Q, Sun L, Chiarelli AM, Hislop G, Yaffe MJ, Minkin S (2006) Mammographic density as a surrogate marker for the effects of hormone therapy on risk of breast cancer. Cancer Epidemiol Biomarkers Prev 15: 961-966.
7. Boyd NF, Rommens JM, Vogt K, Lee V, Hopper JL, Yaffe MJ, Paterson AD (2005) Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 6: 798-808.
8. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ (2010) American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28: 3784-3796.
9. Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ (1994) The quantitative analysis of mammographic densities. Phys Med Biol 39: 1629-1638.
10. Cigler T, Richardson H, Yaffe MJ, Fabian CJ, Johnston D, Ingle JN, Nassif E, Brunner RL, Wood ME, Pater JL, Hu H, Qi S, Tu D, Goss PE (2011) A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women. Breast Cancer Res Treat 126: 453-461.
11. Cigler T, Tu D, Yaffe MJ, Findlay B, Verma S, Johnston D, Richardson H, Hu H, Qi S, Goss PE (2010) A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women. Breast Cancer Res Treat 120: 427-435.
12. Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, Forbes JF, Warren RM (2011) Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: A nested case-control study. J Natl Cancer Inst 103: 744-752.
13. Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW (2004) Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 96: 621-628.
14. Desta Z, Kreutz Y, Nguyen AT, Li L, Skaar T, KamdemLK, Henry NL, Hayes DF, Storniolo AM, Stearns V, Hoffmann E, Tyndale RF, Flockhart DA (2011) Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clin Pharmacol Ther 90: 693-700.
15. Douglas JA, Roy-Gagnon MH, Zhou C, Mitchell BD, Shuldiner AR, Chan HP, Helvie MA (2008) Mammographic breast density-evidence for genetic correlations with established breast cancer risk factors. Cancer Epidemiol Biomarkers Prev 17: 3509-3516.
16. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R (2010) Metaanalysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28: 509-518.
17. Ellingjord-Dale M, Lee E, Couto E, Ozhand A, Qureshi SA, Hofvind S, Van Den Berg DJ, Akslen LA, Grotmol T, Ursin G (2012) Polymorphisms in hormone metabolism and growth factor genes and mammographic density in Norwegian postmenopausal hormone therapy users and nonusers. Breast Cancer Res 14: R135.
18. Freedman M, San Martin J, O'Gorman J, Eckert S, Lippman ME, Lo SC, Walls EL, Zeng J (2001) Digitized mammography: A clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. J Natl Cancer Inst 93: 51-56.
19. Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364: 2381-2391.
20. Greendale GA, Palla SL, Ursin G, Laughlin GA, Crandall C, Pike MC, Reboussin BA (2005) The association of endogenous sex steroids and sex steroid binding proteins with mammographic density: Results from the Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study. Am J Epidemiol 162: 826-834.
21. Greenwood CM, Paterson AD, Linton L, Andrulis IL, Apicella C, Dimitromanolakis A, Kriukov V, Martin LJ, Salleh A, Samiltchuk E, Parekh RV, Southey MC, John EM, Hopper JL, Boyd NF, Rommens JM (2011) A genome-wide linkage study of mammographic density, a risk factor for breast cancer. Breast Cancer Res 13: R132.
22. Haiman CA, Bernstein L, Berg D, Ingles SA, Salane M, Ursin G (2002) Genetic determinants of mammographic density. Breast Cancer Res 4: R5.
23. Haiman CA, Hankinson SE, De Vivo I, Guillemette C, Ishibe N, Hunter DJ, Byrne C (2003) Polymorphisms in steroid hormone pathway genes and mammographic density. Breast Cancer Res Treat 77: 27-36.
24. Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA, Stearns V, Hayes DF, Storniolo AM (2012) Predictors of aromatase inhibitor discontinuation due to treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30: 936-942.
25. Henry NL, Giles JT, Ang D, Mohan M, Dadabhoy D, Robarge J, Hayden J, Lemler S, Shahverdi K, Powers P, Li L, Flockhart D, Stearns V, Hayes DF, Storniolo AM, Clauw DJ (2008) Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 111: 365-372.
26. Hong CC, Thompson HJ, Jiang C, Hammond GL, Tritchler D, Yaffe M, Boyd NF (2003) Val158Met polymorphism in catechol-Omethyltransferase gene associated with risk factors for breast cancer. Cancer Epidemiol Biomarkers Prev 12: 838-847.
27. Hong CC, Thompson HJ, Jiang C, Hammond GL, Tritchler D, Yaffe M, Boyd NF (2004) Association between the T27C polymorphism in the cytochrome P450 c17alpha (CYP17) gene and risk factors for breast cancer. Breast Cancer Res Treat 88: 217-230.
28. Kerlikowske K, Ichikawa L, Miglioretti DL, Buist DS, Vacek PM, Smith-Bindman R, Yankaskas B, Carney PA, Ballard-Barbash R (2007) Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk. J Natl Cancer Inst 99: 386-395.
29. Kim J, Han W, Moon HG, Ahn SK, Shin HC, You JM, Han SW, Im SA, Kim TY, Koo HR, Chang JM, Cho N, Moon WK, Noh DY (2012) Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer Breast Cancer Res 14: R102.
30. Li J, Eriksson L, Humphreys K, Czene K, Liu J, Tamimi RM, Lindstrom S, Hunter DJ, Vachon CM, Couch FJ, Scott CG, Lagiou P, Hall P (2010) Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer. Breast Cancer Res 12: R19.
31. Li J, Humphreys K, Eriksson L, Edgren G, Czene K, Hall P (2013) Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal breast cancer patients. J Clin Oncol 31: 2249-2256.
32. Lindstrom S, Vachon CM, Li J, Varghese J, Thompson D, Warren R, Brown J, Leyland J, Audley T, Wareham NJ, Loos RJ, Paterson AD, Rommens J, Waggott D, Martin LJ, Scott CG, Pankratz VS, Hankinson SE, Hazra A, Hunter DJ, Hopper JL, Southey MC, Chanock SJ, Silva Idos S, Liu J, Eriksson L, Couch FJ, Stone J, Apicella C, Czene K, Kraft P, Hall P, Easton DF, Boyd NF, Tamimi RM (2011) Common variants in ZNF365 are associated with both mammographic density and breast cancer risk. Nat Genet 43: 185-187.
33. Martin KE, Helvie MA, Zhou C, Roubidoux MA, Bailey JE, Paramagul C, Blane CE, Klein KA, Sonnad SS, Chan HP (2006) Mammographic density measured with quantitative computer-Aided method: Comparison with radiologists' estimates and BI-RADS categories. Radiology 240: 656-665.
34. Martin LJ, Boyd NF (2008) Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: Hypotheses based on epidemiological evidence. Breast Cancer Res 10: 201.
35. Maskarinec G, Pagano I, Lurie G, Kolonel LN (2006) A longitudinal investigation of mammographic density: The multiethnic cohort. Cancer Epidemiol Biomarkers Prev 15: 732-739.
36. Olson JE, Ma CX, Pelleymounter LL, Schaid DJ, Pankratz VS, Vierkant RA, Fredericksen ZS, Ingle JN, Wu Y, Couch F, Sellers TA, Weinshilboum RM, Vachon CM (2007) A comprehensive examination of CYP19 variation and breast density. Cancer Epidemiol Biomarkers Prev 16: 623-625.
37. Pinsky RW, Helvie MA (2010) Mammographic breast density: Effect on imaging and breast cancer risk. J Natl Compr Canc Netw 8: 1157-1164.
38. Pisano ED, Gatsonis C, Hendrick E, Yaffe M, Baum JK, Acharyya S, Conant EF, Fajardo LL, Bassett L, D'Orsi C, Jong R, Rebner M (2005) Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 353: 1773-1783.
39. Prowell TM, Blackford AL, Byrne C, Khouri NF, Dowsett M, Folkerd E, Tarpinian KS, Powers PP, Wright LA, Donehower MG, Jeter SC, Armstrong DK, Emens LA, Fetting JH, Wolff AC, Garrett-Mayer E, Skaar TC, Davidson NE, Stearns V (2011) Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole. Cancer Prev Res (Phila) 4: 1993-2001.
40. Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S (2001) Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA 285: 171-176.
41. Tamimi RM, Hankinson SE, Colditz GA, Byrne C (2005) Endogenous sex hormone levels and mammographic density among postmenopausal women. Cancer Epidemiol Biomarkers Prev 14: 2641-2647.
42. Ursin G, Lillie EO, Lee E, Cockburn M, Schork NJ, Cozen W, Parisky YR, Hamilton AS, Astrahan MA, Mack T (2009) The relative importance of genetics and environment on mammographic density. Cancer Epidemiol Biomarkers Prev 18: 102-112.
43. Vachon CM, Kuni CC, Anderson K, Anderson VE, Sellers TA (2000) Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States). Cancer Causes Control 11: 653-662.
44. Vachon CM, Suman VJ, Brandt KR, Kosel ML, Buzdar AU, Olson JE, Wu FF, Flickinger LM, Ursin G, Elliott CR, Shepherd L, Weinshilboum RM, Goss PE, Ingle JN (2013) Mammographic breast density response to aromatase inhibition. Clin Cancer Res 19: 2144-2153.
45. Varghese JS, Smith PL, Folkerd E, Brown J, Leyland J, Audley T, Warren RM, Dowsett M, Easton DF, Thompson DJ (2012) The heritability of mammographic breast density and circulating sex-hormone levels; two independent breast cancer risk factors. Cancer Epidemiol Biomarkers Prev 72: 1478-1484.
46. Warren R, Skinner J, Sala E, Denton E, Dowsett M, Folkerd E, Healey CS, Dunning A, Doody D, Ponder B, Luben RN, Day NE, Easton D (2006) Associations among mammographic density, circulating sex hormones, and polymorphisms in sex hormone metabolism genes in postmenopausal women. Cancer Epidemiol Biomarkers Prev 15: 1502-1508.
47. Wei J, Chan HP, Helvie MA, Roubidoux MA, Sahiner B, Hadjiiski LM, Zhou C, Paquerault S, Chenevert T, Goodsitt MM (2004) Correlation between mammographic density and volumetric fibroglandular tissue estimated on breast MR images. Med Phys 31: 933-942.
48. Zhou C, Chan HP, Petrick N, Helvie MA, Goodsitt MM, Sahiner B, Hadjiiski LM (2001) Computerized image analysis: Estimation of breast density on mammograms. Med Phys 28: 1056-1069.